Andere Kunden interessierten sich auch für
![Selective Antibiotic Use in Respiratory Illness: a Family Practice Guide]( "Selective Antibiotic Use in Respiratory Illness: a Family Practice Guide")
Selective Antibiotic Use in Respiratory Illness: a Family Practice Guide67,99 €![Allergens and Airway Hyperreactivity]( "Allergens and Airway Hyperreactivity")
Allergens and Airway Hyperreactivity74,99 €![Noncommunicable Diseases]( "Noncommunicable Diseases")
Noncommunicable Diseases74,99 €![Respiratory Health]( "Respiratory Health")
Respiratory Health74,99 €![Allergens and Airway Hyperreactivity]( "Allergens and Airway Hyperreactivity")
Allergens and Airway Hyperreactivity74,99 €![A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics]( "A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics")
A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics147,99 €![Methods in Asthmology]( "Methods in Asthmology")
Methods in Asthmology37,99 €
Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled beta2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled beta2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.